51. Tranexamic acid decreases blood loss in shoulder arthroplasty: A meta-analysis.
- Author
-
Yu BF, Yang GJ, Li Q, and Liu LL
- Subjects
- Aged, Antifibrinolytic Agents administration & dosage, Antifibrinolytic Agents adverse effects, Clinical Trials as Topic, Female, Hemoglobins analysis, Humans, Male, Tranexamic Acid administration & dosage, Tranexamic Acid adverse effects, Antifibrinolytic Agents therapeutic use, Arthroplasty, Replacement, Shoulder methods, Blood Loss, Surgical prevention & control, Blood Transfusion statistics & numerical data, Tranexamic Acid therapeutic use
- Abstract
Background: The objective of this meta-analysis was to evaluate the efficacy and safety of tranexamic acid (TXA) in shoulder arthroplasty (SA)., Methods: Academic articles were identified from the Cochrane Library, Medline (1966-2017.2), PubMed (1966-2017.2), Embase (1980-2017.2), and ScienceDirect (1966-2017.2). Randomized controlled trials (RCTs) and non-RCTs studying TXA in SA were included. Two independent reviewers conducted independent data abstraction. The I statistic was used to assess heterogeneity. Fixed- or random-effects models were used for meta-analysis., Results: Two RCTs and 2 non-RCTs met the inclusion criteria. This meta-analysis found significant differences in postoperative hemoglobin reduction (MD = -0.71 g/dL), drainage volume (MD = -133.21 mL), and total blood loss (MD = -226.82 mL) between TXA groups and controls. There were no significant differences in blood transfusion requirements, operation time, or length of hospital stay., Conclusions: The use of TXA in SA decreases postoperative hemoglobin reduction, drainage volume, and total blood loss and does not increase the risk of complications. Because of the limited high-quality evidence currently available, additional randomized controlled trials are required.
- Published
- 2017
- Full Text
- View/download PDF